1,2,3-benzotriazin-4(3H)-one 1-oxide | 122081-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并-1,2,3-三嗪类化合物
• 英文名称: 1,2,3-benzotriazin-4(3H)-one 1-oxide
• CAS: 122081-98-5
• 化学式: C₇H₅N₃O₂
• 分子量: 163.136
• InChiKey: CKPHFPVPPMKXBQ-UHFFFAOYSA-N

物化性质

• 熔点：
  153-155 °C(Solv: ethanol (64-17-5))
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.44
• 重原子数：
  12.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.69
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 1,2,3-benzotriazin-4(3H)-one 1-oxide 以 乙醚 为溶剂， 以74%的产率得到3-methyl-1,2,3-benzotriazin-4(3H)-one 1-oxide
  参考文献：
  名称：

  1,2,3-苯并三嗪酮1-氧化物

  摘要：

  3-取代的1,2,3-苯并三嗪-4（3 H）-在3-烷基-和3-甲氧基-1,2,3-苯并三嗪-4（3 H）-的过酸氧化反应中形成3-取代的1,2,3-苯并三嗪-4（3 H）-。那些。可以将3-（α-烷氧基烷基）1-氧化物衍生物脱烷基化为互变异构的3-未取代的化合物。比较了1,2,3-苯并三嗪酮系统的异构N-氧化物的酸度。碘代二乙酸苯基酯将邻硝基苯甲醛苄基和苯基hydr转化为2-取代的4-氧化-1,2,3-苯并三嗪1-氧化物甜菜碱（1）。

  DOI：

  10.1039/p19890000543
• 作为产物：
  描述：

  1,2,3-苯并三嗪-4-酮 在 盐酸 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 反应 90.0h， 生成 1,2,3-benzotriazin-4(3H)-one 1-oxide
  参考文献：
  名称：

  1,2,3-苯并三嗪酮1-氧化物

  摘要：

  3-取代的1,2,3-苯并三嗪-4（3 H）-在3-烷基-和3-甲氧基-1,2,3-苯并三嗪-4（3 H）-的过酸氧化反应中形成3-取代的1,2,3-苯并三嗪-4（3 H）-。那些。可以将3-（α-烷氧基烷基）1-氧化物衍生物脱烷基化为互变异构的3-未取代的化合物。比较了1,2,3-苯并三嗪酮系统的异构N-氧化物的酸度。碘代二乙酸苯基酯将邻硝基苯甲醛苄基和苯基hydr转化为2-取代的4-氧化-1,2,3-苯并三嗪1-氧化物甜菜碱（1）。

  DOI：

  10.1039/p19890000543

文献信息

• [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE<br/>[FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2010136755A1

  公开（公告）日：2010-12-02

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O ); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  该发明提供了式（1）的化合物或其盐或互变异构体；其中X1为N或N+（O-）；X2为N或CH；Q为C1-3烷基基团；R1从氢、C1-4烃基和羟基-C2-4烃基中选择；R2、R3和R4相同或不同，每个从氢、氟、氯和甲基中选择；Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环，或者是一个萘环；Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增殖性疾病。
• [EN] MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER<br/>[FR] MODULATEURS DE LA P70S6 KINASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES CÉRÉBRAUX ET DU CANCER DU SEIN TRIPLE NÉGATIF
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2016131776A1

  公开（公告）日：2016-08-25

  The invention provides compounds for use in the treatment of a disease or condition selected from brain disorders and triple-negative breast cancer, the compounds being of the formula (1) or a salt or tautomer thereof; wherein: X1 is N or N+(O'); X2 is N or CH; Q is selected from a C1-3 alkylene group, cyclopropane-1,1-diyl and cyclobutane- 1,1-diyl; R1 is selected from hydrogen and C1-4 alkyl;R2, R3 and R4 are the same or different and each is selected from hydrogen and fluorine; Ar1 is a benzene, thiophene, naphthyl or pyridine ring optionally substituted with 1, 2 or 3 substituents selected from fluorine; chlorine; bromine; CM hydrocarbyl; C1-4 hydrocarbyloxy; trifluoromethyl; difluoromethyl; cyano; trifluoromethoxy; difluoromethoxy; Ar2 is a monocyclic 5- or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S and being optionally substituted with 1, 2 or 3 substituents selected from fluorine; C1-4 hydrocarbyl; amino; mono-C1-4 hydrocarbylamino and di-C1-4 hydrocarbylamino; and wherein, in each substituent consisting of or containing C1-4 hydrocarbyl, the C1-4 hydrocarbyl is selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, cyclopropyl, cyclobutyl and cyclopropylmethyl.

  该发明提供了用于治疗脑部疾病和三阴性乳腺癌等疾病或症状的化合物，该化合物为以下公式（1）或其盐或互变异构体；其中：X1为N或N+(O')；X2为N或CH；Q从C1-3烷基、环丙烷-1,1-二基和环丁烷-1,1-二基中选择；R1从氢和C1-4烷基中选择；R2、R3和R4相同或不同，每个从氢和氟中选择；Ar1为苯、噻吩、萘或吡啶环，可选择地取代1、2或3个从氟、氯、溴、CM烃基、C1-4烃基氧、三氟甲基、二氟甲基、氰、三氟甲氧基、二氟甲氧基中选择的取代基；Ar2为含有1、2或3个来自O、N和S的杂原子环成员的单环5-或6-成员杂环环，可选择地取代1、2或3个从氟、C1-4烃基、氨基、单C1-4烃基氨基和双C1-4烃基氨基中选择的取代基；在每个由或含有C1-4烃基的取代基中，C1-4烃基从C1-4烷基、C2-4烯基、C2-4炔基、环丙基、环丁基和环丙基甲基中选择。
• [EN] SUBSTITUTED QUINOXALINES AND BENZOTRIAZINE P70S6 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYPE QUINOXALINES ET BENZOTRIAZINE SUBSTITUÉES DE LA P70S6 KINASE
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2016170163A1

  公开（公告）日：2016-10-27

  The invention provides compounds that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (0), or a salt, tautomer or N-oxide thereof; wherein: X1 is N or N+(0-); X2 is N or CH; Q1 is an optionally substituted C1-8 alkylene; Q2 is a bond or an optionally substituted C1-8 alkylene group; R1 is selected from hydrogen and a group Cy1; Cy1 is an optionally substituted 4 to 7 membered monocyclic non-aromatic carbocyclic or heterocyclic group containing 0, 1 or 2 heteroatom ring members selected from O and S and oxidised forms of S; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine, C1-2 alkyl and C1-2 alkoxy, wherein each C1-2 alkyl and C1-2 alkoxy is optionally substituted with two or more fluorine atoms; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring Ar2 is an optionally substituted bicyclic 8 to 1 1 -membered heteroaryl group containing 1, 2, 3 or 4 heteroatom ring members selected from O, N and S. The compounds are useful in medicine, for example in the treatment of a disease or condition selected from cancers (e.g. triple negative breast cancer, brain tumours and brain metastases arising from non-brain cancers), neurodevelopmental diseases (e.g. Fragile X syndrome) and neurodegenerative diseases.

  该发明提供了抑制或调节p70S6激酶活性的化合物，该化合物的结构如下式（0），或其盐、互变异构体或N-氧化物；其中：X1为N或N+(0-)；X2为N或CH；Q1为可选择取代的C1-8烷基；Q2为键或可选择取代的C1-8烷基基团；R1选自氢和Cy1基团；Cy1为可选择取代的含有0、1或2个来自O和S的杂原子环成员的4到7成员单环非芳香碳环或杂环基团及S的氧化形式；R2、R3和R4相同或不同，每个选自氢、氟、氯、C1-2烷基和C1-2烷氧基，其中每个C1-2烷基和C1-2烷氧基可选择地取代为两个或更多氟原子；Ar1为可选择取代的含有0、1或2个来自O、N和S的杂原子环成员的单环5或6成员芳基或杂芳基环，或一个萘环；Ar2为可选择取代的含有1、2、3或4个来自O、N和S的杂原子环成员的双环8到11成员杂芳基基团。这些化合物在医学上有用，例如在治疗癌症（如三阴性乳腺癌、脑肿瘤和来自非脑部癌症的脑转移瘤）、神经发育疾病（如脆性X综合征）和神经退行性疾病等疾病或病况的治疗中。
• SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE
  申请人：Boyle Robert George

  公开号：US20120071478A1

  公开（公告）日：2012-03-22

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X 1 is N or N + (O − ); X 2 is N or CH; Q is a C 1-3 alkylene group; R 1 is selected from hydrogen, C 1-4 hydrocarbyl and hydroxy-C 2-4 hydrocarbyl; R 2 , R 3 and R 4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar 1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar 2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  本发明提供公式（1）的化合物：或其盐或互变异构体；其中X1为N或N +（O-）; X2为N或CH; Q为C1-3烷基基团; R1选择自氢，C1-4烃基和羟基-C2-4烃基; R2，R3和R4相同或不同，且每个选择自氢，氟，氯和甲基; Ar1为含有0、1或2个杂环环成员（选自O，N和S）的可选择取代的单环5或6成员芳基或杂芳基环，或萘环；Ar2为含有1、2或3个杂环环成员（选自O，N和S）的可选择取代的单环5或6成员杂芳基环。公式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增生性疾病。
• Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase
  申请人：Boyle Robert George

  公开号：US08716473B2

  公开（公告）日：2014-05-06

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O−); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  本发明提供式（1）的化合物或其盐或互变异构体; 其中X1为N或N+（O−）; X2为N或CH; Q为C1-3烷基; R1选自氢，C1-4烃基和羟基-C2-4烃基; R2，R3和R4相同或不同，且每个选自氢，氟，氯和甲基; Ar1为可选取代的单环5或6成员芳基或杂芳基环，其中包含0，1或2个杂原子环成员，选自O，N和S，或萘环；Ar2为可选取代的单环5或6成员杂芳基环，其中包含1，2或3个杂原子环成员，选自O，N和S。式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增殖性疾病。